Michael Willis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Willis has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Andreas Nilsson
The Swedish Institute for Health Economics (IHE), Lund, Sweden
9 shared publications- Christian Asseburg
ESiOR Oy, Kuopio, Finland
7 shared publications - Andreas Nilsson
The Swedish Institute for Health Economics, Lund, Sweden
6 shared publications - Cheryl Neslusan
Janssen Scientific Affairs, LLC, Titusville, NJ, USA
6 shared publications - Pierre Johansen
Novo Nordisk A/S, Søborg, Denmark
5 shared publications Cheryl Neslusan
Janssen Scientific Affairs, LLC, Titusville, USA
4 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 14 (11) , e250125
The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada
Aim: Continuous glucose monitoring (CGM) supports glycemic control and reduces diabetes complications. CGM systems include intermittently scanned CGM (is-CGM) and real-time CGM (rt-CGM). While rt-CGM may provide better outcomes than is-CGM, it costs more upfront and its cost-effectiveness in Canada has not been established. We assessed the cost-effectiveness of rt-CGM versus is-CGM in people with insulin-treated Type 2 diabetes mellitus (T2DM) from a Canadian healthcare payer perspective. Materials & methods: We used the ECHO-T2DM microsimulation model to estimate incremental lifetime health outcomes and costs of rt-CGM versus is-CGM. Clinical inputs came from an indirect treatment comparison; cost and utility data were drawn from published sources. Sensitivity analyses tested robustness. Results: Rt-CGM was more effective and less costly than is-CGM, yielding 0.346 additional quality-adjusted life-years and CAD 2237 in savings over 30 years. Benefits stemmed primarily from better glycemic control and fewer complications, reductions in glycemic events, and reduced fear of hypoglycemia. Although rt-CGM incurred CAD 3867 higher acquisition costs, these were more than offset by avoided complications. Deterministic analysis showed dominance in 14 of 18 scenarios, and cost-effectiveness in the remaining four. Uncertainty analysis showed rt-CGM had an ICER below CAD 50,000 in 98% of simulations. Discussion: Rt-CGM is potentially a cost-saving alternative to is-CGM among people with insulin-treated T2DM in Canada. This finding was strengthened by rigorous sensitivity analysis. Study strengths include use of a validated microsimulation model and adoption of conservative assumptions. Limitations include absence of head-to-head trial evidence and indirect use of time in and out of range. Conclusion: Rt-CGM is a potentially cost-saving option for managing insulin-treated T2DM in Canada, with implications for clinical practice and reimbursement policy.
- 1 November 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 14 (11) , e250125
Open AccessThe cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada
Aim: Continuous glucose monitoring (CGM) supports glycemic control and reduces diabetes complications. CGM systems include intermittently scanned CGM (is-CGM) and real-time CGM (rt-CGM). While rt-CGM may provide better outcomes than is-CGM, it costs more upfront and its cost-effectiveness in Canada has not been established. We assessed the cost-effectiveness of rt-CGM versus is-CGM in people with insulin-treated Type 2 diabetes mellitus (T2DM) from a Canadian healthcare payer perspective. Materials & methods: We used the ECHO-T2DM microsimulation model to estimate incremental lifetime health outcomes and costs of rt-CGM versus is-CGM. Clinical inputs came from an indirect treatment comparison; cost and utility data were drawn from published sources. Sensitivity analyses tested robustness. Results: Rt-CGM was more effective and less costly than is-CGM, yielding 0.346 additional quality-adjusted life-years and CAD 2237 in savings over 30 years. Benefits stemmed primarily from better glycemic control and fewer complications, reductions in glycemic events, and reduced fear of hypoglycemia. Although rt-CGM incurred CAD 3867 higher acquisition costs, these were more than offset by avoided complications. Deterministic analysis showed dominance in 14 of 18 scenarios, and cost-effectiveness in the remaining four. Uncertainty analysis showed rt-CGM had an ICER below CAD 50,000 in 98% of simulations. Discussion: Rt-CGM is potentially a cost-saving alternative to is-CGM among people with insulin-treated T2DM in Canada. This finding was strengthened by rigorous sensitivity analysis. Study strengths include use of a validated microsimulation model and adoption of conservative assumptions. Limitations include absence of head-to-head trial evidence and indirect use of time in and out of range. Conclusion: Rt-CGM is a potentially cost-saving option for managing insulin-treated T2DM in Canada, with implications for clinical practice and reimbursement policy.
- Open Access
- 22 June 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 944-963
Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting
AimsEconomic simulation models, such as the IHE Type 2 Diabetes Cohort Model (IHE-DCM-T2), are used widely to inform resource allocation for Type 2 Diabetes (T2D) treatments. Recently, IHE-DCM-T2 was augmented with Japanese-specific risk equations for coronary heart disease, stroke, non-proliferative and proliferative retinopathy, macroalbuminuria, and non-CV mortality to better align with the Japanese healthcare context. This study aims to update and extend prior model validation of IHE-DCM-T2 to cover the Japanese risk equations for model applications intended for Japan's clinical setting and healthcare system.Materials and MethodsFace validity was assessed through expert review of model assumptions and structure. Model programming was verified by detailed code review and 728 stress tests designed to identify errors in logic and in programming. Predictive accuracy was tested by comparing model predictions to real-world outcomes from 28 Japanese studies, assessing concordance visually, with best-fitting regression lines, and with mean absolute percentage error (MAPE), root mean square percentage error (RMSPE), mean squared logarithmic error (MSLE), and mean squared log-absolute error (MSLAR). Subgroup analyses examined dependent and independent endpoints, along with mortality, microvascular, and macrovascular outcomes. Sensitivity analyses assessed model robustness to variations in scale and validation study sample size.ResultsIHE-DCM-T2 demonstrated face validity and correct implementation. External validation against 120 endpoints showed good alignment between predicted and observed event rates, with a regression line slope of 0.96 and an R2 of 0.98. Overall, the prediction error metrics were: MAPE = 0.83, RMSPE = 1.21, MSLE = 0.61, and MSLAR = 0.53. As expected, predictions were more accurate for dependent than independent endpoints. Among endpoint categories, macrovascular events had the lowest average errors, whereas mortality endpoints had the highest MAPE and RMSPE, and microvascular endpoints had the highest MSLE and MSLAR. Predictive accuracy was consistent across alternative test specifications.LimitationsLimitations included gaps in validation data, as studies often omit necessary information, and the requirement for long-term follow-up that inherently reflects past treatment patterns. Additionally, some gaps in the Japanese risk equations required the use of complementary non-Japanese risk equations. To ensure robustness, only studies with at least 1,000 patients were included in the validation studies, which may introduce selection bias.ConclusionsThis comprehensive validation of the IHE-DCM-T2, augmented with Japanese-specific risk equations, demonstrated its suitability for health technology assessments and resource allocation decisions for T2D in the Japanese clinical setting and healthcare system.
- 22 June 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 944-963
Open AccessValidation of the IHE type 2 diabetes cohort model in the Japanese clinical setting
AimsEconomic simulation models, such as the IHE Type 2 Diabetes Cohort Model (IHE-DCM-T2), are used widely to inform resource allocation for Type 2 Diabetes (T2D) treatments. Recently, IHE-DCM-T2 was augmented with Japanese-specific risk equations for coronary heart disease, stroke, non-proliferative and proliferative retinopathy, macroalbuminuria, and non-CV mortality to better align with the Japanese healthcare context. This study aims to update and extend prior model validation of IHE-DCM-T2 to cover the Japanese risk equations for model applications intended for Japan's clinical setting and healthcare system.Materials and MethodsFace validity was assessed through expert review of model assumptions and structure. Model programming was verified by detailed code review and 728 stress tests designed to identify errors in logic and in programming. Predictive accuracy was tested by comparing model predictions to real-world outcomes from 28 Japanese studies, assessing concordance visually, with best-fitting regression lines, and with mean absolute percentage error (MAPE), root mean square percentage error (RMSPE), mean squared logarithmic error (MSLE), and mean squared log-absolute error (MSLAR). Subgroup analyses examined dependent and independent endpoints, along with mortality, microvascular, and macrovascular outcomes. Sensitivity analyses assessed model robustness to variations in scale and validation study sample size.ResultsIHE-DCM-T2 demonstrated face validity and correct implementation. External validation against 120 endpoints showed good alignment between predicted and observed event rates, with a regression line slope of 0.96 and an R2 of 0.98. Overall, the prediction error metrics were: MAPE = 0.83, RMSPE = 1.21, MSLE = 0.61, and MSLAR = 0.53. As expected, predictions were more accurate for dependent than independent endpoints. Among endpoint categories, macrovascular events had the lowest average errors, whereas mortality endpoints had the highest MAPE and RMSPE, and microvascular endpoints had the highest MSLE and MSLAR. Predictive accuracy was consistent across alternative test specifications.LimitationsLimitations included gaps in validation data, as studies often omit necessary information, and the requirement for long-term follow-up that inherently reflects past treatment patterns. Additionally, some gaps in the Japanese risk equations required the use of complementary non-Japanese risk equations. To ensure robustness, only studies with at least 1,000 patients were included in the validation studies, which may introduce selection bias.ConclusionsThis comprehensive validation of the IHE-DCM-T2, augmented with Japanese-specific risk equations, demonstrated its suitability for health technology assessments and resource allocation decisions for T2D in the Japanese clinical setting and healthcare system.
- Open Access
- 8 March 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (6) , 601-616
A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care
Patient-centered care emphasizes individual preferences, but insurer coverage decisions—based on population-level evidence—may restrict treatment options for patients who differ from the average. This highlights the importance of considering heterogeneity, which refers to differences in health and cost outcomes that are systematically linked to variations in factors like patient characteristics, insurer policies, and provider practices. Failing to account for heterogeneity in economic evaluations can lead to suboptimal decisions, inferior outcomes, and inefficiency. This study aimed to assess the tools and methods for addressing heterogeneity in economic evaluations, examine the extent to which, and how, heterogeneity has been addressed in US cost-utility studies, and provide insights and recommendations to promote more fuller consideration of heterogeneity in US economic evaluations. We reviewed and adapted a seminal taxonomy of heterogeneity to the US setting, highlighting key drivers like patient preferences and insurance design. Methods for addressing heterogeneity in economic evaluations were also reviewed and summarized. We used data from the Tufts Medical Center Cost-Effectiveness Analysis Registry to assess empirical practices in US cost-utility applications, specifically the frequency, types, and impact of a subgroup analysis, and whether rationales for including or excluding subgroups were provided. The revised taxonomy highlights key drivers of heterogeneity in the diverse and decentralized US healthcare ecosystem, such as the diversity of patient preferences and in non-patient factors like access to healthcare providers and insurance coverage. Methods to explore, confirm, and incorporate heterogeneity into a comparative economic analysis exist, but are often challenged by data availability. In addition to the trade-off between potential efficiency gains and increasing uncertainty in comparative value estimates, ethical implications of stratified decisions were highlighted in the literature. We found that a subgroup analysis was rare, and primarily performed for clinical factors like age and disease severity. Only 2 of the 85 studies published between 2015 and 2022 with subgroup-level results were found to consider non-patient factors, and none considered preferences. One-third of studies reported incremental cost-effectiveness ratios differing by more than 50% from the unstratified estimate. No studies provided a rationale for omitting a subgroup analysis, and only two motivated inclusion of a subgroup analysis, limiting our ability to assess the appropriateness of these decisions. Despite well-documented methods to address heterogeneity, its application is limited in US cost-utility studies, especially regarding patient preferences and non-patient factors. As these factors often drive real-world health outcomes and costs in the USA, proper consideration of, and reporting on, heterogeneity is essential to avoid erroneous market access decisions, suboptimal patient outcomes, and economic inefficiency. Future efforts, including work by an upcoming Professional Society of Pharmacoeconomics and Outcomes Research Task Force, should continue to refine taxonomies and emphasize the importance of addressing heterogeneity.
- 8 March 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (6) , 601-616
Open AccessA Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care
Patient-centered care emphasizes individual preferences, but insurer coverage decisions—based on population-level evidence—may restrict treatment options for patients who differ from the average. This highlights the importance of considering heterogeneity, which refers to differences in health and cost outcomes that are systematically linked to variations in factors like patient characteristics, insurer policies, and provider practices. Failing to account for heterogeneity in economic evaluations can lead to suboptimal decisions, inferior outcomes, and inefficiency. This study aimed to assess the tools and methods for addressing heterogeneity in economic evaluations, examine the extent to which, and how, heterogeneity has been addressed in US cost-utility studies, and provide insights and recommendations to promote more fuller consideration of heterogeneity in US economic evaluations. We reviewed and adapted a seminal taxonomy of heterogeneity to the US setting, highlighting key drivers like patient preferences and insurance design. Methods for addressing heterogeneity in economic evaluations were also reviewed and summarized. We used data from the Tufts Medical Center Cost-Effectiveness Analysis Registry to assess empirical practices in US cost-utility applications, specifically the frequency, types, and impact of a subgroup analysis, and whether rationales for including or excluding subgroups were provided. The revised taxonomy highlights key drivers of heterogeneity in the diverse and decentralized US healthcare ecosystem, such as the diversity of patient preferences and in non-patient factors like access to healthcare providers and insurance coverage. Methods to explore, confirm, and incorporate heterogeneity into a comparative economic analysis exist, but are often challenged by data availability. In addition to the trade-off between potential efficiency gains and increasing uncertainty in comparative value estimates, ethical implications of stratified decisions were highlighted in the literature. We found that a subgroup analysis was rare, and primarily performed for clinical factors like age and disease severity. Only 2 of the 85 studies published between 2015 and 2022 with subgroup-level results were found to consider non-patient factors, and none considered preferences. One-third of studies reported incremental cost-effectiveness ratios differing by more than 50% from the unstratified estimate. No studies provided a rationale for omitting a subgroup analysis, and only two motivated inclusion of a subgroup analysis, limiting our ability to assess the appropriateness of these decisions. Despite well-documented methods to address heterogeneity, its application is limited in US cost-utility studies, especially regarding patient preferences and non-patient factors. As these factors often drive real-world health outcomes and costs in the USA, proper consideration of, and reporting on, heterogeneity is essential to avoid erroneous market access decisions, suboptimal patient outcomes, and economic inefficiency. Future efforts, including work by an upcoming Professional Society of Pharmacoeconomics and Outcomes Research Task Force, should continue to refine taxonomies and emphasize the importance of addressing heterogeneity.
- 1 January 2025
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 31 (1) , 69-81
Cost-effectiveness models of non–small cell lung cancer: A systematic literature review
Non-small cell lung cancer (NSCLC) presents a formidable global health challenge owing to significant morbidity, high mortality rates, and substantial economic burden. Recent advances in targeted therapies and immunotherapies have transformed NSCLC treatment, but efficacy varies across patients. Tailoring treatment to patients can improve outcomes and potentially improve cost-effectiveness (ie, value for money) as well. For NSCLC, cost-effectiveness must often be estimated using economic modeling, and estimates are only as good as the models. Existing cost-effectiveness models are not necessarily suitable for evaluating personalized medicines. To identify and assess cost-effectiveness models of NSCLC. We searched for studies indexed in PubMed and Embase from 2012 to October 2023 that described cost-effectiveness models of NSCLC. Study details were extracted, summarized, and evaluated for adherence to the Consolidated Health Economic Evaluation Reporting Standards. We identified 237 unique models, 40% of which were published in 2022 or 2023. Despite cross-model heterogeneity, most models used the same 3 health states (progression-free survival, progressive disease, and death) combined with time-to-event equations that characterize risks. Thirty models included a diagnostic component, most of which considered guiding treatment selection using biomarkers. Adherence to the overall Consolidated Health Economic Evaluation Reporting Standards checklist was generally incomplete, and adherence to a subset of model-related questions even more so. The large number of models that were found, almost half of which were published since 2022, underscores the importance of cost-effectiveness analysis in NSCLC. Variable adherence to best practices suggests opportunities for improvement, however, and making high-quality, open-source models available to researchers may be valuable.
- 1 January 2025
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 31 (1) , 69-81
Cost-effectiveness models of non–small cell lung cancer: A systematic literature review
Non-small cell lung cancer (NSCLC) presents a formidable global health challenge owing to significant morbidity, high mortality rates, and substantial economic burden. Recent advances in targeted therapies and immunotherapies have transformed NSCLC treatment, but efficacy varies across patients. Tailoring treatment to patients can improve outcomes and potentially improve cost-effectiveness (ie, value for money) as well. For NSCLC, cost-effectiveness must often be estimated using economic modeling, and estimates are only as good as the models. Existing cost-effectiveness models are not necessarily suitable for evaluating personalized medicines. To identify and assess cost-effectiveness models of NSCLC. We searched for studies indexed in PubMed and Embase from 2012 to October 2023 that described cost-effectiveness models of NSCLC. Study details were extracted, summarized, and evaluated for adherence to the Consolidated Health Economic Evaluation Reporting Standards. We identified 237 unique models, 40% of which were published in 2022 or 2023. Despite cross-model heterogeneity, most models used the same 3 health states (progression-free survival, progressive disease, and death) combined with time-to-event equations that characterize risks. Thirty models included a diagnostic component, most of which considered guiding treatment selection using biomarkers. Adherence to the overall Consolidated Health Economic Evaluation Reporting Standards checklist was generally incomplete, and adherence to a subset of model-related questions even more so. The large number of models that were found, almost half of which were published since 2022, underscores the importance of cost-effectiveness analysis in NSCLC. Variable adherence to best practices suggests opportunities for improvement, however, and making high-quality, open-source models available to researchers may be valuable.
- 1 September 2024
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 30 (9) , 1041-1056
Budget impact models for lung cancer interventions: A systematic literature review
BACKGROUND: Budget impact models (BIMs) forecast the financial implications of adopting new technologies and the potential need for budget reallocation, thus playing a crucial role in reimbursement decisions. Despite the importance of accurate forecasts, studies indicate large discrepancies between estimates and reality. We are developing an artificial intelligence-based clinical decision tool to identify patients with non-small cell lung cancer who are most likely to benefit from immunotherapy. OBJECTIVE: To evaluate the budgetary implications and describe a systematic literature review of published lung cancer BIMs. METHODS: We searched PubMed and EMBASE for studies published between 2010 and 2023 that include BIMs that describe lung cancer interventions. Forward and backward reference searches were performed for all qualifying studies. We extracted author and publication year, country, interventions, disease stages, time horizon, analytical perspective, modeling methods used, types of costs included, sensitivity analyses conducted, and data sources used. We then evaluated adherence to the Professional Society for Health Economics and Pharmacoeconomics Research best-practice guidelines. RESULTS: A total of 25 BIMs were identified, spanning 14 different countries. Model structure could not be ascertained definitively for nearly half of the models. The cost calculator approach was most common among the others. Time horizons ranged from 1 to 5 years, in line with recommendations. Most models compared drugs, 4 compared nondrug interventions, and 7 compared diagnostic technologies. Assumptions about market uptake were poorly documented and poorly motivated. Inclusion of cancer-related costs was rare. Adherence to best practices was variable and did not appear to improve over time. CONCLUSIONS: The number of published BIMs for lung cancer exceeded expectations. There were modest trends toward publication frequency and model quality over time. Our analysis revealed variability across the models, as well as their adherence to best practices, indicating substantial room for improvement. Although none of the models were individually suitable for the purpose of evaluating an artificial intelligence-based treatment selection tool, some models provided valuable insights.
- 1 September 2024
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 30 (9) , 1041-1056
Budget impact models for lung cancer interventions: A systematic literature review
BACKGROUND: Budget impact models (BIMs) forecast the financial implications of adopting new technologies and the potential need for budget reallocation, thus playing a crucial role in reimbursement decisions. Despite the importance of accurate forecasts, studies indicate large discrepancies between estimates and reality. We are developing an artificial intelligence-based clinical decision tool to identify patients with non-small cell lung cancer who are most likely to benefit from immunotherapy. OBJECTIVE: To evaluate the budgetary implications and describe a systematic literature review of published lung cancer BIMs. METHODS: We searched PubMed and EMBASE for studies published between 2010 and 2023 that include BIMs that describe lung cancer interventions. Forward and backward reference searches were performed for all qualifying studies. We extracted author and publication year, country, interventions, disease stages, time horizon, analytical perspective, modeling methods used, types of costs included, sensitivity analyses conducted, and data sources used. We then evaluated adherence to the Professional Society for Health Economics and Pharmacoeconomics Research best-practice guidelines. RESULTS: A total of 25 BIMs were identified, spanning 14 different countries. Model structure could not be ascertained definitively for nearly half of the models. The cost calculator approach was most common among the others. Time horizons ranged from 1 to 5 years, in line with recommendations. Most models compared drugs, 4 compared nondrug interventions, and 7 compared diagnostic technologies. Assumptions about market uptake were poorly documented and poorly motivated. Inclusion of cancer-related costs was rare. Adherence to best practices was variable and did not appear to improve over time. CONCLUSIONS: The number of published BIMs for lung cancer exceeded expectations. There were modest trends toward publication frequency and model quality over time. Our analysis revealed variability across the models, as well as their adherence to best practices, indicating substantial room for improvement. Although none of the models were individually suitable for the purpose of evaluating an artificial intelligence-based treatment selection tool, some models provided valuable insights.
- Open Access
- 7 December 2022
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 28 (2) , 86-95
Real-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics
Purpose: Hypertension is a leading causeof premature death worldwide and a major public health problem. This study investigated the long-term effects (>1 year) of digital hypertension monitoring by home blood pressure (HBP) measurements in combination with individualized remote treatment via a Swedish Digital Therapeutics platform in a large patient population. Methods: The primary endpoint, HBP, and exploratory endpoints, BMI, alcohol consumption, stress level, physical activity, and smoking, were assessed every 3 months for 540 and 360 days, respectively, in 7752 Swedish primary hypertension patients. Patients received individualized medical treatments and lifestyle advice via asynchronous text-based communication in an app. Changes from baseline in endpoints were calculated for the whole population and for subgroups defined by baseline SBP ≥135 (high SBP), 125–135 (suboptimal SBP), 115–125 (optimal SBP), and <115 mmHg (low SBP). Results: After 360 days of treatment, the whole population showed a significant increase of 57% (from 37 to 58%) in the proportion of patients with controlled SBP (i.e. SBP of 115–135 mmHg). The largest reduction in SBP of 13.8 mmHg was observed for the high SBP subgroup, whereas for the low SBP subgroup, SBP increased by 13.4 mmHg. BP improved most in the first three months, and for both the high and low BP subgroups, the improvement continued during the 540-day study period. Significant beneficial changes were also observed for some exploratory endpoints including BMI and smoking. Conclusions: In conclusion, the digital therapeutics platform was associated with significant improvement in BP control and associated risk factors, which were maintained over a longer period.
- 7 December 2022
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 28 (2) , 86-95
Open AccessReal-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics
Purpose: Hypertension is a leading causeof premature death worldwide and a major public health problem. This study investigated the long-term effects (>1 year) of digital hypertension monitoring by home blood pressure (HBP) measurements in combination with individualized remote treatment via a Swedish Digital Therapeutics platform in a large patient population. Methods: The primary endpoint, HBP, and exploratory endpoints, BMI, alcohol consumption, stress level, physical activity, and smoking, were assessed every 3 months for 540 and 360 days, respectively, in 7752 Swedish primary hypertension patients. Patients received individualized medical treatments and lifestyle advice via asynchronous text-based communication in an app. Changes from baseline in endpoints were calculated for the whole population and for subgroups defined by baseline SBP ≥135 (high SBP), 125–135 (suboptimal SBP), 115–125 (optimal SBP), and <115 mmHg (low SBP). Results: After 360 days of treatment, the whole population showed a significant increase of 57% (from 37 to 58%) in the proportion of patients with controlled SBP (i.e. SBP of 115–135 mmHg). The largest reduction in SBP of 13.8 mmHg was observed for the high SBP subgroup, whereas for the low SBP subgroup, SBP increased by 13.4 mmHg. BP improved most in the first three months, and for both the high and low BP subgroups, the improvement continued during the 540-day study period. Significant beneficial changes were also observed for some exploratory endpoints including BMI and smoking. Conclusions: In conclusion, the digital therapeutics platform was associated with significant improvement in BP control and associated risk factors, which were maintained over a longer period.
- Open Access
- 6 March 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (6) , 1038-1046
The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs
Aim: To estimate the fiscal burden for taxpayers in Sweden associated with type 2 diabetes (T2D) attributed to diabetes‐related complications in patients failing to meet HbA1c targets. Material and Methods: We developed a public economic framework to assess how changes in diabetes‐related complications influenced projected tax contributions and government disability payments for people with T2D. The analysis applied accepted disease‐modelling practices to estimate different rates of diabetes‐related complications based on an HbA1c of 6.9% (52 mmol/mol) and of 6.0% (42 mmol/mol). We adjusted the employment activity rates for those experiencing T2D‐related events, applying age‐specific earnings to estimate lifetime tax losses. Furthermore, the likelihood of receiving payments for health‐related employment inactivity was estimated. Direct healthcare costs are excluded from this analysis. Results: The estimated per person earnings loss for immediate and delayed HbA1c control was Swedish krona (SEK) 42 299 and SEK 44 157, respectively, over 10 years. The lost employment activity of people with T2D translates to lost tax revenues of SEK 23 265 and SEK 24 287 for immediate and delayed control, respectively. The estimated difference in disability payments was SEK 538. Combining the tax revenue loss and excess disability payments defines the broader fiscal costs, where we observe combined fiscal losses that favour immediate and sustained control by SEK 1560 over 10 years. Conclusions: We show that conducting fiscal analysis of diabetes interventions offers an enriched perspective capturing a range of costs that fall on government in relation to lost tax revenue and disability payments. Tax‐financed health systems may benefit from broadening the consideration of costs and benefits when evaluating new interventions and treatment practices.
- 6 March 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (6) , 1038-1046
Open AccessThe public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs
Aim: To estimate the fiscal burden for taxpayers in Sweden associated with type 2 diabetes (T2D) attributed to diabetes‐related complications in patients failing to meet HbA1c targets. Material and Methods: We developed a public economic framework to assess how changes in diabetes‐related complications influenced projected tax contributions and government disability payments for people with T2D. The analysis applied accepted disease‐modelling practices to estimate different rates of diabetes‐related complications based on an HbA1c of 6.9% (52 mmol/mol) and of 6.0% (42 mmol/mol). We adjusted the employment activity rates for those experiencing T2D‐related events, applying age‐specific earnings to estimate lifetime tax losses. Furthermore, the likelihood of receiving payments for health‐related employment inactivity was estimated. Direct healthcare costs are excluded from this analysis. Results: The estimated per person earnings loss for immediate and delayed HbA1c control was Swedish krona (SEK) 42 299 and SEK 44 157, respectively, over 10 years. The lost employment activity of people with T2D translates to lost tax revenues of SEK 23 265 and SEK 24 287 for immediate and delayed control, respectively. The estimated difference in disability payments was SEK 538. Combining the tax revenue loss and excess disability payments defines the broader fiscal costs, where we observe combined fiscal losses that favour immediate and sustained control by SEK 1560 over 10 years. Conclusions: We show that conducting fiscal analysis of diabetes interventions offers an enriched perspective capturing a range of costs that fall on government in relation to lost tax revenue and disability payments. Tax‐financed health systems may benefit from broadening the consideration of costs and benefits when evaluating new interventions and treatment practices.
- 27 December 2021
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 77 (6) , 945-954
Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium
The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial showed reduced renal and cardiovascular (CV) events in patients with type 2 diabetes...
- 27 December 2021
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 77 (6) , 945-954
Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium
The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial showed reduced renal and cardiovascular (CV) events in patients with type 2 diabetes...
- 26 April 2021
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 144 (2) , 170-178
Swedish guidelines for device‐aided therapies in Parkinson's disease —Economic evaluation and implementation
Objectives The National Board of Health and Welfare in Sweden published the national guidelines for Parkinson's Disease 2016. The aim of this study was to summarize this evidence review and development of the guidelines, focusing on the economic evaluation of device‐aided therapies (deep brain stimulation, pump‐based infusion of levodopa‐carbidopa intestinal gel or apomorphine) for Parkinson's disease, and the rate of implementation after 3 years in Sweden. Material and methods The evidence review underlying the guidelines—including systematic literature searches of clinical and economic evidence, model‐based economic evaluation, and formal analysis and guideline development—was examined, condensed, and translated. The impact of the guidelines was assessed with treatment use statistics from 2009 to 2019. Results All device‐aided therapies were assigned high priority. Based on a relatively low proportion of device‐aided therapies (30%) in Parkinson's disease, a 5‐year increase of 500 patients was recommended. This was estimated to reduce total costs by SEK 14 million (€1.7 million). Follow‐up data found an increase of 217 patients between 2017 and 2019, following the same trend as before the guidelines. Conclusion Three years after the guidelines were published, the use of device‐aided therapies has increased in Sweden, albeit not in pace with recommendations. One reason for slow implementation may be poor incentivization related to budget silos in which the costs for device‐aided therapies are borne by the regions but the cost offsets (eg, reduced need for home care) are reaped by local stakeholders.
- 26 April 2021
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 144 (2) , 170-178
Swedish guidelines for device‐aided therapies in Parkinson's disease —Economic evaluation and implementation
Objectives The National Board of Health and Welfare in Sweden published the national guidelines for Parkinson's Disease 2016. The aim of this study was to summarize this evidence review and development of the guidelines, focusing on the economic evaluation of device‐aided therapies (deep brain stimulation, pump‐based infusion of levodopa‐carbidopa intestinal gel or apomorphine) for Parkinson's disease, and the rate of implementation after 3 years in Sweden. Material and methods The evidence review underlying the guidelines—including systematic literature searches of clinical and economic evidence, model‐based economic evaluation, and formal analysis and guideline development—was examined, condensed, and translated. The impact of the guidelines was assessed with treatment use statistics from 2009 to 2019. Results All device‐aided therapies were assigned high priority. Based on a relatively low proportion of device‐aided therapies (30%) in Parkinson's disease, a 5‐year increase of 500 patients was recommended. This was estimated to reduce total costs by SEK 14 million (€1.7 million). Follow‐up data found an increase of 217 patients between 2017 and 2019, following the same trend as before the guidelines. Conclusion Three years after the guidelines were published, the use of device‐aided therapies has increased in Sweden, albeit not in pace with recommendations. One reason for slow implementation may be poor incentivization related to budget silos in which the costs for device‐aided therapies are borne by the regions but the cost offsets (eg, reduced need for home care) are reaped by local stakeholders.
- 13 February 2021
- Published by Springer Nature in PharmacoEconomics
- Vol. 39 (4) , 447-461
Macrovascular Risk Equations Based on the CANVAS Program
Background Widely used risk equations for cardiovascular outcomes for individuals with type 2 diabetes mellitus (T2DM) have been incapable of predicting cardioprotective effects observed in recent cardiovascular outcomes trials (CVOTs) involving individuals with T2DM at high risk for or with established cardiovascular disease (CVD). Objective We developed cardiovascular and mortality risk equations using patient-level data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program to address this shortcoming. Methods Data from 10,142 patients with T2DM at high risk for or with established CVD, randomized to canagliflozin + standard of care (SoC) or SoC alone and followed for a mean duration of 3.6 years in the CANVAS Program were used to derive parametric risk equations for myocardial infarction (MI), stroke, hospitalization for heart failure (HHF), and death. Accumulated knowledge from the widely used UKPDS-OM2 (United Kingdom Prospective Diabetes Study Outcomes Model 2) was leveraged, and any departures in parameterization were limited to those necessary to provide adequate goodness of fit. Candidate explanatory covariates were selected using only the placebo arm to minimize confounding effects. Internal validation was performed separately by study treatment arm. Results UKPDS-OM2 predicted CANVAS Program outcomes poorly. Recalibrating UKPDS-OM2 intercepts improved calibration in some cases. Refitting the coefficients but otherwise preserving the UKPDS-OM2 structure improved the fit substantially, which was sufficient for stroke and death. For MI, reselecting UKPDS-OM2 covariates and functional form proved sufficient. For HHF, selection from a broad set of candidate covariates and inclusion of a canagliflozin indicator was required. Conclusion These risk equations address some of the limitations of widely used risk equations, such as the UKPDS-OM2, for modeling cardioprotective treatments for individuals with T2DM and high cardiovascular risk, including derivation from overly healthy patients treated with agents that lack cardioprotection and have been described as reflecting a different therapeutic era. Future work is needed to examine external validity.
- 13 February 2021
- Published by Springer Nature in PharmacoEconomics
- Vol. 39 (4) , 447-461
Macrovascular Risk Equations Based on the CANVAS Program
Background Widely used risk equations for cardiovascular outcomes for individuals with type 2 diabetes mellitus (T2DM) have been incapable of predicting cardioprotective effects observed in recent cardiovascular outcomes trials (CVOTs) involving individuals with T2DM at high risk for or with established cardiovascular disease (CVD). Objective We developed cardiovascular and mortality risk equations using patient-level data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program to address this shortcoming. Methods Data from 10,142 patients with T2DM at high risk for or with established CVD, randomized to canagliflozin + standard of care (SoC) or SoC alone and followed for a mean duration of 3.6 years in the CANVAS Program were used to derive parametric risk equations for myocardial infarction (MI), stroke, hospitalization for heart failure (HHF), and death. Accumulated knowledge from the widely used UKPDS-OM2 (United Kingdom Prospective Diabetes Study Outcomes Model 2) was leveraged, and any departures in parameterization were limited to those necessary to provide adequate goodness of fit. Candidate explanatory covariates were selected using only the placebo arm to minimize confounding effects. Internal validation was performed separately by study treatment arm. Results UKPDS-OM2 predicted CANVAS Program outcomes poorly. Recalibrating UKPDS-OM2 intercepts improved calibration in some cases. Refitting the coefficients but otherwise preserving the UKPDS-OM2 structure improved the fit substantially, which was sufficient for stroke and death. For MI, reselecting UKPDS-OM2 covariates and functional form proved sufficient. For HHF, selection from a broad set of candidate covariates and inclusion of a canagliflozin indicator was required. Conclusion These risk equations address some of the limitations of widely used risk equations, such as the UKPDS-OM2, for modeling cardioprotective treatments for individuals with T2DM and high cardiovascular risk, including derivation from overly healthy patients treated with agents that lack cardioprotection and have been described as reflecting a different therapeutic era. Future work is needed to examine external validity.